Cowen Initiates Coverage on Uniqure (NASDAQ:QURE)

Cowen began coverage on shares of Uniqure (NASDAQ:QURE) in a research report issued on Tuesday, The Fly reports. The firm set an “outperform” rating on the biotechnology company’s stock.

Several other research analysts also recently commented on QURE. ValuEngine downgraded shares of Uniqure from a “buy” rating to a “hold” rating in a research note on Tuesday. Goldman Sachs Group initiated coverage on shares of Uniqure in a research report on Tuesday. They set a “buy” rating for the company. Mizuho assumed coverage on shares of Uniqure in a report on Thursday, September 12th. They issued a “buy” rating and a $67.00 price target on the stock. Sanford C. Bernstein initiated coverage on shares of Uniqure in a research report on Tuesday, September 24th. They issued an “outperform” rating and a $73.00 price objective on the stock. Finally, Chardan Capital reaffirmed a “buy” rating on shares of Uniqure in a research note on Tuesday, September 3rd. Two analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $74.43.

Shares of Uniqure stock opened at $54.78 on Tuesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 14.33 and a quick ratio of 14.33. The business’s 50 day simple moving average is $50.31 and its two-hundred day simple moving average is $57.63. The stock has a market capitalization of $2.43 billion, a P/E ratio of -23.41 and a beta of 0.79. Uniqure has a one year low of $24.07 and a one year high of $82.49.

Uniqure (NASDAQ:QURE) last released its quarterly earnings data on Monday, October 28th. The biotechnology company reported ($0.58) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.23. The firm had revenue of $1.05 million during the quarter, compared to analyst estimates of $2.24 million. Uniqure had a negative return on equity of 51.12% and a negative net margin of 1,670.86%. Sell-side analysts expect that Uniqure will post -2.98 earnings per share for the current fiscal year.

In other Uniqure news, VP Alexander Edward Kuta III sold 4,000 shares of the firm’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $52.08, for a total value of $208,320.00. Following the completion of the sale, the vice president now directly owns 45,578 shares in the company, valued at $2,373,702.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Matthew C. Kapusta sold 8,000 shares of Uniqure stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $47.31, for a total value of $378,480.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 40,769 shares of company stock worth $1,945,826. Insiders own 2.91% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Griffin Asset Management Inc. purchased a new position in shares of Uniqure in the 2nd quarter valued at approximately $39,000. US Bancorp DE boosted its position in shares of Uniqure by 275.5% during the second quarter. US Bancorp DE now owns 582 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 427 shares in the last quarter. Botty Investors LLC bought a new stake in shares of Uniqure during the second quarter valued at approximately $78,000. Rockefeller Capital Management L.P. purchased a new stake in Uniqure in the second quarter worth $78,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Uniqure by 21.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,975 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 346 shares during the period. Hedge funds and other institutional investors own 72.56% of the company’s stock.

Uniqure Company Profile

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

Read More: Most Volatile Stocks

The Fly

Analyst Recommendations for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with's FREE daily email newsletter.